To synthesise evidence concerning the effect of anti-epileptic drugs (AEDs) for seizure prevention, and to contrast their effectiveness for provoked versus unprovoked seizures.
Results of the review
Forty-seven studies with a total of 8,218 patients were included in the review.
Prevention of provoked seizures.
For each of the drugs and conditions, the estimated effect indicated a lower seizure rate with the AED. The decrease in seizures was significant in 7 of the 19 situations.
For recurrence of febrile seizures, phenobarbital produced the only significant decrease in seizures (RR 0.51, 95% CI: 0.32, 0.82, p<0.01). Intermittent diazepam, valproate, intermittent phenobarbital and phenytoin did not produce significant results.
For seizures accompanying cerebral malaria, phenobarbital was the only AED investigated; it produced a significant decrease in seizures (RR 0.36, 95% CI: 0.23, 0.56, p<0.01).
For seizures after perinatal asphyxia, phenobarbital was the only AED investigated; it did not produce a significant decrease in seizures.
For alcohol-related seizures, lorazepam produced the only significant decrease in seizures (RR 0.12, 95% CI: 0.04, 0.40, p<0.01). Valproate, phenytoin and carbamazepine did not produce significant results.
For contrast media-associated seizures, diazepam was the only AED investigated; it produced a significant decrease in seizures (RR 0.10, 95% CI: 0.01, 0.79, p=0.03).
Only one study investigated brain tumour-related seizures, it found that phenobarbital or phenytoin did not produce a significant decrease in seizures.
For postcraniotomy seizures, phenytoin produced a significant decrease in seizures (RR 0.42, 95% CI: 0.25, 0.71, p<0.01) whereas carbamazepine did not.
Finally, for post-traumatic brain injury seizures, phenytoin (RR 0.33, 95% CI: 0.19, 0.59, p<0.01) and carbamazepine (RR 0.39, 95% CI: 0.17, 0.92, p=0.03) produced a significant decrease in seizures, whereas phenobarbital and phenytoin plus phenobarbital did not.
Prevention of provoked and unprovoked seizures.
Only one study investigated postcraniotomy seizures, it found that valproate did not produce a significant decrease in seizures.
For post-traumatic brain injury seizures, phenytoin (RR 0.13, 95% CI: 0.04, 0.59, p<0.01) produced a significant decrease in seizures, whereas phenytoin plus phenobarbital did not.
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Suppression or prevention of unprovoked or epileptic seizures.
No condition or drug combination produced significant results. In 4 of the 13 combinations, the estimated RR exceeded 1; in another 4 it exceeded 1 for either all studies or for placebo-controlled studies, favouring the control over the AED. Conclusive evidence against clinically important effectiveness (considered as a greater than 25% decrease in seizures) was available for a number of drugs and conditions. Valproate had little or no effect in preventing unprovoked seizures after traumatic brain injury, and carbamazepine had little or no effect on unprovoked seizures after craniotomy.
Authors' conclusions
Effective or promising results predominate for provoked (acute, symptomatic) seizures. For unprovoked (epileptic) seizures, no drug has been shown to be effective, and some have had a clinically important effect ruled out.
CRD commentary
The research question and the study selection criteria were clearly stated and the literature search was comprehensive. Attempts were made to identify unpublished studies and there did not appear to be any language restrictions. The author did not report a method for making decisions on the relevance of studies for the review, nor for assessing the validity of those included.
Details of the primary studies were tabulated in adequate detail. The author reported that heterogeneity was assessed, although the specific test used was not stated. The meta-analysis was appropriate, although only one study was identified for some conditions and treatment types.
The results which achieved statistical significance were summarised narratively. The author's conclusions are justified.
Implications of the review for practice and research
Practice: The author states that clinical use of any drug to prevent epileptogenesis should be avoided until clinical trials have proven the drug to be effective for that purpose.
Research: The author states that rigorous clinical trials are needed to evaluate the effects of new drugs on epileptogenesis. She also states that a broader range of conditions might be considered for future trials, such as certain strokes and aneurysms, as well as encephalitis with early seizures, perinatal asphyxia with early seizures and symptomatic status epilepticus, as these conditions may have sufficient risk for developing epilepsy and sufficient prevalence to make evaluation of antiepileptogenesis both justifiable and practical.
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